Recent studies suggest an association between HCV infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis.

Petta, S., Adinolfi, L.E., Fracanzani, A.L., Rini, F., Caldarella, R., Calvaruso, V., et al. (2018). Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis. JOURNAL OF HEPATOLOGY, 69(1), 18-24 [10.1016/j.jhep.2018.02.015].

Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis

Petta, Salvatore
;
Rini, Francesca;Caldarella, Rosalia;Calvaruso, Vincenza;Cammà, Calogero;Ciaccio, Marcello;Di Marco, Vito;Grimaudo, Stefania;Licata, Anna;Pipitone, Rosaria Maria;Pinto, Antonio;Torres, Daniele;Tuttolomondo, Antonino;Craxì, Antonio
2018-01-01

Abstract

Recent studies suggest an association between HCV infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis.
https://www.sciencedirect.com/science/article/pii/S0168827818301326?via=ihub
Petta, S., Adinolfi, L.E., Fracanzani, A.L., Rini, F., Caldarella, R., Calvaruso, V., et al. (2018). Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis. JOURNAL OF HEPATOLOGY, 69(1), 18-24 [10.1016/j.jhep.2018.02.015].
File in questo prodotto:
File Dimensione Formato  
PETTA S ET JHEP 2018.pdf

accesso aperto

Tipologia: Post-print
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF Visualizza/Apri
Hepatitis C virus eradication by direct-acting antiviralagents improves carotid atherosclerosis in patientswith severe liver fibrosis.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 657.04 kB
Formato Adobe PDF
657.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/280690
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 162
social impact